AxoGen, Inc. (NASDAQ:AXGN) management will conduct a conference call for 29th October 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.axogeninc.com
Earnings Expectation
AxoGen, Inc. is set to announce third quarter earning results on Thursday 29th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, AXGN to report 3Q20 loss of $ 0.14 per share. For the full year, analysts anticipate top line of $ 100.89 million, while looking forward to loss of $ 0.63 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 30.00 million ~ $ 30.00 million
Full Year 2020 topline are forecasted in a range of$ 124.00 million ~ $ 128.00 million
Click Here For More Historical Outlooks Of AxoGen, Inc.
AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves. The companys products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
